COVAXX, a U.S. company developing a multitope synthetic peptide-based vaccine to fight COVID-19 pandemic, has announced a global logistics partnership with Maersk.
The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities.
COVAXX is developing UB-612 using a high precision, synthetic peptide platform to activate both B-cell and T-cell arms. COVAXX is currently conducting Phase 1 clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval.
The company has already made advanced commitments for over 100 million doses of UB-612 around the globe
The partnership with Maersk will help COVAXX accomplish its mission of defeating COVID-19 and ultimately democratizing health worldwide.
Under the partnership, Maersk will oversee all logistics activities of the vaccine to ensure efficient transportation to developing countries. The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.
COVAXX is planning to manufacture 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021.
As per COVAXX, the design of the vaccine components will allow for the use of existing cold-chain storage and distribution channels, as the COVAXX vaccine does not require additional infrastructure such as -80⁰C freezers or liquid nitrogen tanks to store materials at extreme temperatures.
“The COVAXX vaccine is unique in that it can be stored in the fridge you have at home, moved in the same trucks that deliver groceries and administered anywhere you can get a flu shot.” – Lou Reese Co-Chief Executive Officer of COVAXX.
“To do what is in the best interests of society at this time of the global health crisis, we are aligning with the strongest leaders in their respective industries to meet the large-scale demand and compliance requirements that we expect. It is not enough to focus on vaccine development and approvals. We must work in parallel to establish the infrastructure and partners with the strongest capabilities, like Maersk, to safely deliver our vaccine around the world.”~ Mei Mei Hu, Co-Chief Executive Officer of COVAXX.
“Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today. A. P. Moller – Maersk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available. Our specialized logistics expertise and the global infrastructure of Maersk make this a perfect match.”~ Rob Townley, Head of Special Project Logistics at Maersk.